Skip to Content
ASPREE is a randomized, double-blind, placebo-controlled study with the purpose of measuring aspirin's capacity to prolong a life free of functional disability—induced by dementia, cancer, and cardiovascular events—in an aging population. The ASPREE study will enroll 6,500 healthy individuals over age 70 in the US and another 12,500 in Australia. Enrollment at the University of Iowa is currently closed (two hundred of the participants were enrolled at the University of Iowa). For more information, visit: www.aspree.org For more information, contact:
Michael Ernst, PharmD 319-384-7756 email@example.com
Copyright © 2015 The University of Iowa. All Rights Reserved.